GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Sumatriptan succinate and naproxen sodium (Treximet), oral tablet

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Treximet - labeled renal guidance

Product / population
Sumatriptan succinate and naproxen sodium (Treximet), oral tablet
Renal method
Creatinine clearance (CrCl), mL/min
Source revision
DailyMed SPL version 8, posted Dec 26, 2024
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Treximet - product and source limitations

Assess kidney function and the NSAID-related risk. This restriction applies to the fixed product.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Treximet - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Sumatriptan succinate and naproxen sodium (Treximet), oral tablet

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 8, posted Dec 26, 2024
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Renal Impairment

Avoid routine use of the sumatriptan/naproxen combination at CrCl below 30 mL/min. Assess kidney function and the NSAID-related risk. This restriction applies to the fixed product.

RDM74-treximet-official-1 · Source locator: Renal guidance: 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42ddf376-8dc0-4236-be2a-0c6ae92ece04
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 8, posted Dec 26, 2024
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
6f5e8ac48337046c1fe40cd2a302ac05da72231849384eb35a74680f75593691

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-treximet&s1=RDM74-treximet-official&h1=90ed632f48d2543550ddbaadb758ed026cb1796e86b4a7c7a07380f44b5fafe8

Top